#+TITLE: Newborn Screening for MPS I
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

:PROPERTIES:
#+DRAWERS: PROPERTIES
#+LaTeX_CLASS: beamer
#+LaTeX_CLASS_OPTIONS: [presentation, smaller]
#+BEAMER_THEME: Hannover
#+BEAMER_COLOR_THEME: whale
#+BEAMER_FRAME_LEVEL: 2
#+COLUMNS: %40ITEM %10BEAMER_env(Env) %9BEAMER_envargs(Env Args) %4BEAMER_col(Col) %10BEAMER_extra(Extra)
#+OPTIONS: H:2 toc:nil
#+PROPERTY: header-args:R :session *R*
#+PROPERTY: header-args :cache no
#+PROPERTY: header-args :tangle yes
#+STARTUP: beamer
#+STARTUP: overview
#+STARTUP: hidestars
#+STARTUP: indent
#+BEAMER_HEADER: \institute[NSO]{Newborn Screening Ontario | The University of Ottawa}
#+BEAMER_HEADER: \titlegraphic{\includegraphics[height=1cm,keepaspectratio]{../logos/NSO_logo.pdf}\includegraphics[height=1cm,keepaspectratio]{../logos/cheo-logo.png} \includegraphics[height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}}
#+latex_header: \hypersetup{colorlinks,linkcolor=white,urlcolor=blue}
#+LaTeX_header: \usepackage{textpos}
#+LaTeX_header: \usepackage{textgreek}
#+LaTeX_header: \usepackage[version=4]{mhchem}
#+LaTeX_header: \usepackage{chemfig}
#+LaTeX_header: \usepackage{siunitx}
#+LaTeX_header: \usepackage{gensymb}
#+LaTex_HEADER: \usepackage[usenames,dvipsnames]{xcolor}
#+LaTeX_HEADER: \usepackage[T1]{fontenc}
#+LaTeX_HEADER: \usepackage{lmodern}
#+LaTeX_HEADER: \usepackage{verbatim}
#+LaTeX_HEADER: \usepackage{tikz}
#+LaTeX_HEADER: \usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
:END:

#+BEGIN_LaTeX

# %\logo{\includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/NSO_logo_small.pdf}~%
# %    \includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}%
# }

\vspace{220pt}
\beamertemplatenavigationsymbolsempty
\setbeamertemplate{caption}[numbered]
\setbeamerfont{caption}{size=\tiny}
#  \addtobeamertemplate{frametitle}{}{%
#  \begin{textblock*}{100mm}(.85\textwidth,-1cm)
#  \includegraphics[height=1cm,width=2cm]{cat}
#  \end{textblock*}}

\tikzstyle{chemical} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=none]
\tikzstyle{hardware} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=gray!30]
\tikzstyle{ms} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{msw} = [rectangle, rounded corners, text width=7em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{label} = [rectangle,text width=8em, minimum height=1em, text centered, draw=none, fill=none]
\tikzstyle{hl} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=red!30]
\tikzstyle{box} = [rectangle, rounded corners, text width=5em, minimum height=5em,text centered, draw=black, fill=none]
\tikzstyle{arrow} = [thick,->,>=stealth]
\tikzstyle{hl-arrow} = [ultra thick,->,>=stealth,draw=red]

#+END_LaTeX

* Introduction
** MPS I 

- Defective \alpha{}-L-iduronidase enzyme
  - degradation of dermatan sulfate and heparin sulfate
- Three clinical subtypes IH, IS and IHS

- The estimated prevalence for MPS1 (all forms) from NBS pilot studies is: 
  - 1/35,500 Washington ​(n~110,000, Scott et al. 2013)
  - 1/14,567 Missouri ​(n=43,701, Hopkins et al. 2015)
  - 1/17,643 Taiwan ​(n=35,285, Lin et al. 2013) 


#+CAPTION[]:
#+NAME: fig:idua
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/idua.png]]


** MPS I disease spectrum

#+CAPTION[]:
#+NAME: fig:mps1
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/mps1clinical.png]]


** Diagnosis and Treatment
# #+CAPTION[]:
# #+NAME: fig:reg
# #+ATTR_LaTeX: :width 0.8\textwidth
# [[file:./figures/registry.png]]


*** Diagnosis
- \alpha{}-L-iduronidase enzyme activity levels
  - measured in WBCs, plasma or fibroblasts \to low to undetectable  
  - unable to distinguish between H/HS/S, there is overlap in the enzymatic levels.
- Two ​IDUA mutations in trans (identified by sequencing)
  - two ‘severe’ alleles \to severe MPS IH
  - one ‘severe’ and one allele that allows some residual enzyme
    activity \to attenuated MPS I

*** Treatment
- hematopoietic stem cell transplantation
- enzyme replacement therapy with Laronidase
- ERT + HSCT in children <2 years of age 


* Biochemistry
** Hydrolysis reaction catalyzed by \alpha-l-iduronidase
#+CAPTION[mech]:Hydrolysis reaction catalyzed by \alpha-l-iduronidase
#+NAME: fig:mech
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/nihms3970f3.jpg]]

*** COMMENT
The catalytic pathway for human IDUA and supporting crystallographic
evidence a) A model of the Michaelis complex with 5F-IdoAF bound in
the active site of IDUA. The enzyme residues are distinguished by
carbon atoms highlighted in green, whereas the ligand carbon atoms in
grey. Hydrogen bonds are represented by dashed lines. (b) The
glycosyl- enzyme intermediate as seen in the active site of IDUA with
Glu299 covalently modified by 2F-IdoAF. The carbon atoms of the enzyme
residues are highlighted in cyan, while those of the ligand are shown
in yellow. (c) A comparative “front” view of the 5F-IdoAF and
covalently bound 2F-IdoA in the active site of IDUA, the C2-C5 axis of
the IdoA ring runs almost perpendicular to the plane of the paper. The
anomeric carbon “travels” ~1.2Å downward from its position in the
IDUA-5F-IdoAF complex to that in the IDUA-2F-IdoA adduct. (d) The
proposed catalytic pathway of IDUA. See text for details. Note that
acid catalysis by Glu 182 may not be important for fluoride departure
but is crucial for the natural substrate of IDUA.


** IDUA exhibits Michaelis-Menten kinetics 

#+begin_src gnuplot :file ./figures/kinetics.pdf
  reset
  set key off 
  set title "IDUA Kinetics"
  set xlabel "Substrate [uM]"
  set xrange [0:2000]
  set ylabel "Rate (nmol/mg/hr)"
  set yrange [0:6]
  f(vmax,km,x) = (vmax*x)/(x + km)
  v(vmax,km,x) = vmax * x/(x + km) 
  vmax1 = 4.42 
  km1 = 191
  km10 = km1*10
  set style line 1 lw 2 lt 1 dt 2 lc rgb "red" 
  set arrow from 0,vmax1 to 2000,vmax1 nohead ls 1
  set label 1 at 50,(vmax1 + 0.2) "Vmax" front
  set label 2 at (km1 + 15),0.5 "Km" front
  set arrow from km1,0 to km1,f(vmax1,km1,km1) lw 2 nohead
  set arrow from 0,v(vmax1,km1,km1) to km1,v(vmax1,km1,km1) lw 2 nohead

  set arrow from km10 ,0 to km10,f(vmax1,km1,km10) lw 2 dt 3 nohead
  set arrow from 0,v(vmax1,km1,km10) to km10,v(vmax1,km1,km10) lw 2 dt 3 nohead

  plot f(vmax1,km1,x) with lines lw 2 lc rgb "midnight-blue"

#+end_src


#+CAPTION[]: IDUA Kinetics, Km = 191 , Vmax = 4.42
#+NAME: fig:mm
#+ATTR_LaTeX: :width 0.8\textwidth
#+RESULTS:
[[file:./figures/kinetics.pdf]]



** Substrate concentration
- substrate concentrations 10-fold the Km recommended
- interference from contaminating 4MU-\beta-D-glucuronide
- high cost of 4MU-\alpha-L-iduronide 
- \alpha-L-iduronidase enzyme assays should be conducted with either:
  - substrate saturating conditions
  - substrate concentrations significantly below enzyme saturation,
    the values are adjusted using Michaelis-Menten model.

\[ 
V  = \frac{Vmax[S]}{Km + [S]}
\]

* Screening Methods

** IDUA: Colorimetric
- phenyl \alpha-l-iduronide
  - Hydrolysis of phenyl \alpha-L-iduronide and subsequent
    colorimetric assay of the liberated phenol
  - Digests contained 5 mM phenyl \alpha-l-iduronide, 0.1 M NaCI,
    and 0.08 M sodium formate buffer of pH 3.5;
  - they were incubated for 18 hr at 25\degree C under a layer of *toluene*.
  - Recovery of the phenol liberated was completed by additional extractions with *toluene*.
  - Phenol was returned to an aqueous phase for analysis by extraction of the pooled *toluene* layers with 0.05 M NaOH.
  - Turbidity was then removed by a treatment with *chloroform-amyl alcohol*.

** Spectrofluorometric
- 4-Methylumbelliferyl-\alpha-L-iduronide is a fluorogenic substrate of \alpha-L-iduronidase
- emission maximum at 445-454 nm.
- excitation maximum for 4-MU is pH-dependent: 330, 370, and 385 nm at pH 4.6, 7.4, and 10.4 

#+CAPTION[4MUI]:4-Methylumbelliferyl-\alpha-L-Iduronide 2-sulfate
#+NAME: fig:4mui
#+ATTR_LaTeX: :width 0.4\textwidth
[[file:./figures/9001600.png]]


** Spectrofluorometric
1. Elute one 3.1 mm DBS punch
   - D-saccharic acid-1,4-lactone: \beta-glucuronidase inhibitor
   - 2 mM 4MU-\alpha-L-iduronide: substrate
2. Incubate for 20hrs at 37\degree C
3. Add glycine-carbonate and vortex to stop reaction
4. 30 minutes at RT
5. Measure fluorescence
   - 4MU calibrator
6. Results uM/L blood/20 hr


** Spectrofluorometric


#+CAPTION: SpotCheck Pro
#+NAME: fig:ap
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/image001.png]]

- modified SpotCheck Pro

** Psuedodeficiency
- Low IDUA /in vitro/ activity with 4-MU substrate 
- p.A300T, steric hindrance at active site E299 
- p.A79T, p.H82Q, p.V322E, p.D223N, p.V322E


** Missouri Program

- 43,701 samples screened by Missouri program using the Baebies assay

#+CAPTION[]:
#+NAME: fig:pd
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/pd.png]]


\[
 PPV = \frac{TP}{TP + FP}  = \frac{1}{1 + (2 + 7 + 2 + 16)} = 0.037
\]

*** Screen Positive and Pseudodeficiency rates
- SPR = 32/43701 =  0.0007322487
  - 150000 samples/year * SPR ~  110 SP/year
- PD rate = 7/43701 = 0.0001601794
  - 150000 samples/year * PD rate ~ 24 PD/year

** IDUA: FIA-MS/MS

#+CAPTION[]:MS/MS workflow
#+NAME: fig:msmswf
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/F2large.jpg]]


\[
\frac{1.7 \text{min/sample} \cdot 1000 \text{samples/day}}{60 \text{min/hour} \cdot 2 \text{instruments}}
= 14.17 \text{hours/instrument/day}
\]

** IDUA: FIA-MS/MS
- Positive mode ESI
- Ten uL of the 150 uL sample via flow injection
  - 80/20 acetonitrile/water with 0.2% formic acid
  - flow-rate of 0.1 mL/min for 1 min then 1 mL/min for 0.5 min.
  - Data was collected during 1.5 minute of infusion,

#+CAPTION[]:IDUA transitions
#+LABEL: tab:mrm
| Analyte | transition     |
|---------+----------------|
| IDUA-IS | 377.2 -> 277.1 |
| IDUA-P  | 391.2 -> 291.2 |

- 25/26 patients with reduced leukocyte activity also had reduced
  activity in DBS using MS/MS substrate (Pollard, presentation)

** GAGs: LC-MS/MS
- Dried blood spot punches (1/8 in. diameter) were eluted for 10 min at RT and sonicated for 15 min.
- Heparan sulfate and dermatan sulfate in the DBS punches were
  digested to disaccharides by with 5 mIU of each heparinase I, II,
  III and 50 mIU chondroitinase B.
- 2 h of incubation at 30\degree C, 15 μL 150 mM EDTA (pH7.0) and
  125 ng internal standard, 4UA-2S-GlcNCOEt-6S, was added and the
  reaction was stopped and proteins denatured by boiling for 5 min.
- The reaction mixture was centrifuged at 16,000 g for 5 min at room
  temperature. The supernatant was subsequently applied to an Amicon
  Ultra 30 K centrifugal filter and centrifuged at 14,000 g

** Inlet table                                                     :noexport:
#+tblname: data-table
| Time | Flow |   %A |   %B |
|------+------+------+------|
|    0 |  0.2 |  100 |    0 |
|  2.5 |  0.2 | 80.0 | 20.0 |
|  5.0 |  0.2 | 80.0 | 20.0 |
|  5.1 |  0.2 |  100 |    0 |
|  7.1 |  0.2 |  100 |    0 |

** GAGs: LC-MS/MS

#+begin_src gnuplot :var data=data-table :file ./figures/outletmethod.png
reset
set key center right
set title "UPLC Gradient"
set xlabel "min"

set xrange [0:8]

set ylabel "percent"
set yrange [0:100]

plot data u 1:3 w lp lw 2 title '10 mM NH4HCO3', \
     data u 1:4 w lp lw 2 title '10% Acetonitrile'

#+end_src

#+RESULTS:
[[file:./figures/outletmethod.png]]


\[
\frac{7.5 \text{min/sample} \cdot 1000 \text{samples/day}}{60 \text{min/hour} \cdot 7 \text{instruments}}
= 17.86 \text{hours/instrument/day}
\]

** Proposed Hurler workflow
#+BEGIN_SRC dot :file ./figures/wf.pdf :cmdline -Kdot -Tpdf
    digraph {
        start[label= "sample",shape="box", style=rounded];
        enzyme[label="IDUA activity \n fluorometric",shape="diamond", fillcolor=steelblue3, style=filled];
        gags[label="GAGs \n LC-MS/MS",shape="diamond", fillcolor=grey80, style=filled];
        ngs[label = "IDUA \n NGS", shape="diamond", fillcolor=steelblue3 style=filled];
        neg[label = "screen negative", shape="box"];
        pos[label = "screen positive", shape="box"];
        start -> enzyme;
        enzyme -> ngs[label="positive"];
        enzyme -> gags[label="borderline"];
        enzyme -> neg[label="negative"];
        gags -> ngs[label="positive"];
        gags -> neg[label="negative"];
        ngs -> neg[label="negative"];
        ngs -> pos[label="positive"];
  }
#+END_SRC


#+CAPTION[]:Proposed Hurler workflow
#+NAME: fig:wf
#+ATTR_LaTeX: :height 0.8\textheight
#+RESULTS:
[[file:./figures/wf.pdf]]

